Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.
Lenart K, Arcoverde Cerveira R, Hellgren F, Ols S, Sheward DJ, Kim C, Cagigi A, Gagne M, Davis B, Germosen D, Roy V, Alter G, Letscher H, Van Wassenhove J, Gros W, Gallouët AS, Le Grand R, Kleanthous H, Guebre-Xabier M, Murrell B, Patel N, Glenn G, Smith G, Loré K. Lenart K, et al. Among authors: glenn g. NPJ Vaccines. 2024 Jan 20;9(1):17. doi: 10.1038/s41541-024-00806-2. NPJ Vaccines. 2024. PMID: 38245545 Free PMC article.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Alves K, et al. Among authors: glenn gm. N Engl J Med. 2023 Mar 2;388(9):857-859. doi: 10.1056/NEJMc2215509. Epub 2023 Jan 25. N Engl J Med. 2023. PMID: 36734884 Free PMC article. No abstract available.
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
Logue J, Johnson RM, Patel N, Zhou B, Maciejewski S, Foreman B, Zhou H, Portnoff AD, Tian JH, Rehman A, McGrath ME, Haupt RE, Weston SM, Baracco L, Hammond H, Guebre-Xabier M, Dillen C, Madhangi M, Greene AM, Massare MJ, Glenn GM, Smith G, Frieman MB. Logue J, et al. Among authors: glenn gm. Nat Commun. 2023 Feb 28;14(1):1130. doi: 10.1038/s41467-022-35606-6. Nat Commun. 2023. PMID: 36854666 Free PMC article.
The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century.
Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, Carnrot C, Shinde V, Smith G, Glenn G, Fries L, Lövgren Bengtsson K. Stertman L, et al. Among authors: glenn g. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37113023 Free PMC article. Review.
[No title available]
[No authors listed] [No authors listed] PMID: 37970668
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
Bennett C, Rivers EJ, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, Pardey TM, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Buchanan A, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM. Bennett C, et al. Among authors: glenn gm. J Infect Dis. 2024 Jul 25;230(1):e4-e16. doi: 10.1093/infdis/jiad508. J Infect Dis. 2024. PMID: 39052718 Free PMC article. Clinical Trial.
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E, Dunkle LM, Madhi SA, Gay CL, Heath PT, Kotloff KL, Smith K, Chau G, Galbiati S, McGarry A, Woo W, Cho I, Alves K, Áñez G, Bennett C, Shinde V, Fries L, Mallory RM, Glenn GM, Toback S. Underwood E, et al. Among authors: glenn gm. Expert Rev Vaccines. 2023 Jan-Dec;22(1):501-517. doi: 10.1080/14760584.2023.2218913. Expert Rev Vaccines. 2023. PMID: 37246757 Free article. Review.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Alves K, et al. Among authors: glenn gm. Vaccine. 2023 Jun 29;41(29):4280-4286. doi: 10.1016/j.vaccine.2023.05.051. Epub 2023 Jun 2. Vaccine. 2023. PMID: 37271706 Free PMC article. Clinical Trial.
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, McCallum Pardey TG, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM; Novavax 2019nCoV-311 Study Group. Bennett C, et al. Among authors: glenn gm. Lancet Infect Dis. 2024 Jun;24(6):581-593. doi: 10.1016/S1473-3099(24)00077-X. Epub 2024 Mar 6. Lancet Infect Dis. 2024. PMID: 38460525 Clinical Trial.
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Cai Z, Kalkeri R, Zhu M, Cloney-Clark S, Haner B, Wang M, Osman B, Dent D, Feng SL, Longacre Z, Glenn G, Plested JS. Cai Z, et al. Among authors: glenn g. Microorganisms. 2024 Feb 29;12(3):501. doi: 10.3390/microorganisms12030501. Microorganisms. 2024. PMID: 38543552 Free PMC article.
349 results